A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.

Cyanovirin-N (CV-N) is a 101 amino acid cyanobacterial lectin with potent antiviral activity against HIV, mediated by high-affinity binding to branched N-linked oligomannosides on the viral surface envelope protein gp120. The protein contains two carbohydrate-binding domains, A and B, each of which binds short oligomannosides independently in vitro. The interaction to gp120 could involve either a single domain or both domains simultaneously; it is not clear which mode would elicit the antiviral activity. The model is complicated by the formation of a domain-swapped dimer form, in which part of each domain is exchanged between two monomers, which contains four functional carbohydrate-binding domains. To clarify whether multivalent interactions with gp120 are necessary for the antiviral activity, we engineered a novel mutant, P51G-m4-CVN, in which the binding site on domain A has been knocked out; in addition, a [P51G] mutation prevents the formation of domain-swapped dimers under physiological conditions. Here, we present the crystal structures at 1.8 A of the free and of the dimannose-bound forms of P51G-m4-CVN, revealing a monomeric structure in which only domain B is bound to dimannose. P51G-m4-CVN binds gp120 with an affinity almost 2 orders of magnitude lower than wt CV-N and is completely inactive against HIV. The tight binding to gp120 is recovered in the domain-swapped version of P51G-m4-CVN, prepared under extreme conditions. Our findings show that the presence of at least two oligomannoside-binding sites, either by the presence of intact domains A and B or by formation of domain-swapped dimers, is essential for activity.

[1]  C J Margulis.  Computational study of the dynamics of mannose disaccharides free in solution and bound to the potent anti-HIV virucidal protein cyanovirin. , 2005, The journal of physical chemistry. B.

[2]  Chi-Huey Wong,et al.  Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Q. Sattentau,et al.  Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.

[4]  A. Gronenborn,et al.  Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. , 2006, Protein engineering, design & selection : PEDS.

[5]  Erik De Clercq,et al.  Emerging anti-HIV drugs. , 2005 .

[6]  Jean Dubuisson,et al.  Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans* , 2006, Journal of Biological Chemistry.

[7]  Alexander Wlodawer,et al.  The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. , 2002, Structure.

[8]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[9]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .

[10]  M. Boyd,et al.  Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. , 2000, Molecular pharmacology.

[11]  A. Wlodawer,et al.  Cyanovirin-N: a sugar-binding antiviral protein with a new twist , 2003, Cellular and Molecular Life Sciences CMLS.

[12]  Carole A Bewley,et al.  Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants. , 2002, Journal of molecular biology.

[13]  C. Bewley,et al.  Crystal Structures of the HIV-1 Inhibitory Cyanobacterial Protein MVL Free and Bound to Man3GlcNAc2 , 2005, Journal of Biological Chemistry.

[14]  Alexander Wlodawer,et al.  Domain-Swapped Structure of the Potent Antiviral Protein Griffithsin and Its Mode of Carbohydrate Binding , 2006, Structure.

[15]  M. Boyd,et al.  A semiautomated multiparameter approach for anti-HIV drug screening. , 1991, Journal of virological methods.

[16]  A. Gronenborn,et al.  Solution structure of cyanovirin-N, a potent HIV-inactivating protein , 1998, Nature Structural Biology.

[17]  C. Bewley,et al.  Engineering an obligate domain-swapped dimer of cyanovirin-N with enhanced anti-HIV activity. , 2002, Journal of the American Chemical Society.

[18]  C. Bewley,et al.  Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex , 2001 .

[19]  Mike Bray,et al.  Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.

[20]  V S Lamzin,et al.  ARP/wARP and molecular replacement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[21]  Anastassis Perrakis,et al.  Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.

[22]  M. Boyd,et al.  Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses , 2000, Journal of Virology.

[23]  Alexander Wlodawer,et al.  Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides* , 2002, The Journal of Biological Chemistry.

[24]  David Eisenberg,et al.  3D domain swapping: As domains continue to swap , 2002, Protein science : a publication of the Protein Society.

[25]  Angela M Gronenborn,et al.  Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity. , 2004, Structure.

[26]  A. Gronenborn,et al.  Design and initial characterization of a circular permuted variant of the potent HIV‐inactivating protein cyanovirin‐N , 2002, Proteins.

[27]  S J Wodak,et al.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. , 1999, Acta crystallographica. Section D, Biological crystallography.

[28]  Carolyn R. Bertozzi,et al.  Chemical Glycobiology , 2001, Science.

[29]  K. Gustafson,et al.  Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin , 2003, Antimicrobial Agents and Chemotherapy.

[30]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[31]  M. Boyd,et al.  Domain-swapped structure of a mutant of cyanovirin-N. , 2002, Biochemical and biophysical research communications.

[32]  A. Gronenborn,et al.  The domain-swapped dimer of cyanovirin-N contains two sets of oligosaccharide binding sites in solution. , 2002, Biochemical and biophysical research communications.

[33]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[34]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[35]  C. Broder,et al.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation , 1994, Journal of virology.

[36]  A. Gronenborn,et al.  The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. , 2005, Mini reviews in medicinal chemistry.

[37]  A. Gronenborn,et al.  Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. , 1999, Journal of molecular biology.

[38]  A. Gronenborn,et al.  Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. , 2002, Chemistry & biology.

[39]  A. Gronenborn,et al.  Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. , 2002, Protein expression and purification.

[40]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[41]  D. Eisenberg,et al.  Domain swapping: entangling alliances between proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.